Subscribe
Subscribe
MY AMERICAN SCIENTIST
LOG IN! REGISTER!
SEARCH
 
Logo IMG
HOME > PAST ISSUE > COMMENTS

Just-as-good Medicine


Comments


I suspect the "lower quality at lower cost" issue is regulatory. The FDA requires that new pharma (and soon will enforce this for devices) provides better outcomes than existing drugs. They do not consider costs. Generics are supposed to take care of that. So, no R&D driven company will invest in new med technology that is unlikely to be approved. Change the regulatory incentives and you may be able to introduce some new innovations.
posted by Carolyn Merkel
March 8, 2010 @ 2:08 PM


I suspect the "lower quality at lower cost" issue is regulatory. The FDA requires that new pharma (and soon will enforce this for devices) provides better outcomes than existing drugs. They do not consider costs. Generics are supposed to take care of that. So, no R&D driven company will invest in new med technology that is unlikely to be approved. Change the regulatory incentives and you may be able to introduce some new innovations.
posted by Carolyn Merkel
March 8, 2010 @ 2:08 PM

 

Read Past Issues on JSTOR

JSTOR, the online academic archive, contains complete back issues of American Scientist from 1913 (known then as the Sigma Xi Quarterly) through 2005.

The table of contents for each issue is freely available to all users; those with institutional access can read each complete issue.

View the full collection here.


Indexes

Year-end indexes in PDF format:

2006

2007

2008

2009

2010


Subscribe to Free eNewsletters!


Write for American Scientist

Review our submission guidelines.


Subscribe to American Scientist